Ann: MGC Reaches 1,000 Prescription Milestone Ahead of Schedule, page-47

As I mentioned earlier, the biggest problem for MXC at this moment is poor management and the price of its product.

As we can see the management keep telling lies to their shareholders.

For instance, the valuation of CannaGlobal, the expected revenue of Cannepil from authorised prescriber scheme (They used to claim the expected revenue will be $ 1 million / 100 patients, and now change to "potential revenue", with only 500 patients they boost the prescription number by 2 to "1,000 prescriptions" , YuShop failure etc. etc.

I am not too faimiliar with the healthcare system in UK, but there is no way Cannepil will be listed under PBS if its price is so more dearer compared to its competitor.

Consider more dilution (substantial CR + dual listing ) is coming, I don't think it is a good time to buy at this moment. But again, investors should use their critical thinking.

All I do here is to present facts and my analysis. But at the end of day, it is you that should make the judgement and decision.